Publication

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Nature Metabolism 2(5):413–431, 2020

Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ

View publication

Subjects
Therapeutic AreaDIO mouseTargetMouseCompoundMethod/EndpointAMLN DIO-NASH (AMLN DIO-MASH) mouseSpeciesAMLN ob/ob-NASH (AMLN ob/ob-MASH) mouseBody weightBlood biochemistryNon-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)CotadutideGLP-1 receptorGlucagon receptorHistopathology scoreIntraperitoneal glucose tolerance test (IPGTT)Image analysisLiver biopsyLiver morphometryReal-time food intake/activity analysisLiraglutideObeticholic acid

Share this page

Resource Library

Related resources
Publication
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy
Poster
Disease progression in the non-obese CDAA-HFD mouse model of advanced NASH and fibrosis
Publication
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis
Poster
Hepatoprotective effects of a HSD17b13 inhibitor in the CDAA-HFD mouse model of advanced MASH with progressive fibrosis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top